Genetic Testing Market Projected to Surge Past $62 Billion by 2035 as Clinical Adoption Deepens

The global genetic testing industry is on a sustained growth trajectory, with a new market analysis from SNS Insider projecting the sector will reach USD 62.61 billion by 2035. The forecast, released today, underscores a fundamental shift in how genetic information is being integrated across clinical settings — from oncology and rare disease diagnosis to prenatal screening and pharmacogenomics. For genomics professionals and laboratory stakeholders, the numbers reflect not just commercial opportunity but a structural transformation in how healthcare systems worldwide are valuing genomic data.

What Is Driving the Growth

Several converging forces are reshaping demand across the genetic testing value chain. Clinical adoption of next-generation sequencing has matured significantly over the past half-decade, with reimbursement pathways in major markets becoming more clearly defined. Liquid biopsy platforms, exemplified by recent FDA clearances for expanded genomic-epigenomic panels, are extending genomic profiling beyond the pathology lab into routine oncology workflows. Meanwhile, the prenatal testing segment continues to expand as non-invasive prenatal testing becomes standard of care in an increasing number of countries. Precision medicine programs at the national level — initiatives now active across Singapore, the United Kingdom, and parts of Europe — are generating population-scale genomic datasets that create downstream demand for validated clinical interpretation tools and certified laboratory services.

Regional Dynamics and Infrastructure Investment

The geographic distribution of this growth tells its own story. While North American and European markets remain the largest by revenue, the Asia-Pacific region is emerging as a critical growth engine. Vietnam's Gene Solutions is pursuing a Hong Kong IPO to fund regional expansion, while Novogene has announced plans to establish its first Australian genomics laboratory at Cabrini Health — a signal that laboratory infrastructure investment is accelerating across markets that were previously underserved. These moves reflect a broader pattern in which genomic services companies are racing to position themselves ahead of anticipated demand rather than reacting to it after the fact. The willingness of capital markets to fund this expansion suggests investor confidence in the sector's long-term fundamentals.

Implications for Genomics Professionals

For clinical laboratory directors, test developers, and genomics platform vendors, a market approaching $62.61 billion represents both validation and challenge. Scale brings competitive intensity, regulatory scrutiny, and growing pressure to demonstrate real-world clinical utility rather than technical capability alone. Laboratories that can integrate genomic testing seamlessly into electronic health records, deliver rapid turnaround times, and support clinicians with actionable interpretation frameworks will be best positioned to capture share in an increasingly crowded field.

The trajectory of this market ultimately signals that genetic testing is completing its transition from specialized tool to foundational infrastructure — and the companies that recognize that distinction earliest will define the industry's next decade.